代孕 | 代孕 | 代孕 | 北京代孕 | 深圳代孕 | 武汉代孕 | 武汉代孕 | 上海代孕 | 武汉代孕 | 捐卵

Investor Relations

The Ambu share has a track record of high performance. And growth is a strong parameter for our success

Latest news

17

May. 2018

Capital increase in connection with exercise of warrants (no. 31)

In December 2013, Ambu A/S issued 2,000,000 warrants and in December 2014 2,000,000 warrants, each warrant entitling the holder to subscribe for one Class B share with a nominal value of DKK 0.50. 52 individuals participate in the 2013 scheme and 22 individuals participate in the 2014 scheme. In both cases, the vesting period is three years, and both schemes can therefore be exercised in the trading window that opened on 7 May 2018 in connection with Ambu’s interim financial report for Q2 2017/18. 

Since 7 may 2018, instructions have been received to exercise warrants as follows: 

  • 2013 scheme: Two individuals have issued instructions to exercise a total of 100,000 warrants at the agreed exercise price of DKK 13.26 per share with a nominal value of DKK 0.50.
  • 2014 scheme: One individual has issued instructions to exercise a total of 140,000 warrants at the agreed exercise price of DKK 23.06 per share with a nominal value of DKK 0.50.

Today Ambu’s Board of Directors decided to carry out the capital increase relating to the exercised warrants.

As a result of the capital increase, the share capital of Ambu will be increased by a nominal amount of DKK 120,000 from DKK 125,392,300 to DKK 125,512,300 through the issue of 240,000 Class B shares.

Following this and in consideration of the employees having left the company, there are 200,000 remaining warrants under the 2013 scheme being held by six individuals and 800,000 remaining warrants under the 2014-scheme being held by 11 individuals.

The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 23 May  2018 under the ISIN code of Ambu A/S’ existing B shares (DK0060946788).

Under section 10 of the Danish Executive Order on disclosure requirements for issuers, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase.

  Number of shares
(nominal value DKK 0.50)
Nominal value
(DKK)
Voting rights
A shares 34,320,000 17,160,000 343,200,000
B shares 216,704,600 108,352,300 216,704,600
Total 251,024,600 125,512,300 559,904,600

Download
You can download this company announcement (pdf).

07

May. 2018

Interim report for Q2 2017/18 and for the half-year (no. 30)

Reporting organic growth in Q2 of 15%, Ambu is well on the way to realising its Big Five 2020 targets with satisfactory gross margins and earnings. The organic growth outlook in local currencies for the year is raised.

Momentum is strong throughout our business with growth of 49% for Visualisation for the half-year and combined growth of 4% for Anaesthesia and PMD. We are succeeding with our initiatives in Europe, the USA and Asia, realising growth rates of 14%, 16% and 16% in the three regions. Strong, double-digit growth over many quarters has transformed Ambu and scaled our earnings to a gross margin in Q2 of 60.5% and an EBIT margin of 24.0%. These are record results for Ambu. We have now been working with Invendo – our latest acquisition – for almost six months, and we are positive about launching a full portfolio of single-use gastrointestinal products before the end of our strategy period in 2020, thereby creating additional potential for growth. In the near term, the solid results for the half-year mean that we are raising our organic growth outlook in local currencies for the full year,” says CEO Lars Marcher.

Highlights

  • Revenue of DKK 651m was posted for Q2, representing growth of 15% in local currencies and 6% in Danish kroner. Half-year growth of 14% in local currencies, or 7% in Danish kroner, was realised. The difference between growth in local currencies and Danish kroner is due to the strengthening of DKK and EUR relative to the US dollar.
  • In Q2, Anaesthesia contributed growth of 8%, Visualisation contributed 43%, and PMD (Patient Monitoring & Diagnostics) delivered growth of 3%, when measured in local currencies. For the half-year, growth was 4% in Anaesthesia, 49% in Visualisation and 3% in PMD.
  • Europe contributed growth of 14%, North America 16%, and the rest of the world also 16%. For the half-year, growth was 13% in Europe, 16% in North America, and 14% in the rest of the world. 
  • The sales figures for endoscopes were 145,000 for Q2, and 249,000 for the half-year, representing increases of 53% and 62% respectively compared to last year. 
  • The gross margin was 60.5% (55.6%) for the quarter, corresponding to an improvement of 4.9 percentage points. For the half-year, the gross margin was 59.4% (54.8%).
  • Total capacity costs for the quarter were DKK 238m (DKK 220m), corresponding to an 8% increase, inclusive of operating expenses in Invendo and more sales resources in the USA. For the half-year, capacity costs were up 9%.
  • EBIT for the quarter was DKK 156m (DKK 121m), corresponding to an EBIT margin of 24.0% (19.7%), and for the half-year DKK 247m (DKK 186m) and 20.5% (16.5%), thus equating to a 4.0 percentage point increase in EBIT margin both for the quarter and for the half-year. 
  • Net working capital relative to revenue has been improved and now accounts for 22% (23%) of revenue over a rolling 12-month period. 
  • Free cash flows before acquisitions of enterprises totalled DKK 22m (DKK 51m) for the quarter, and DKK 58m (DKK 94m) for the half-year. The lower free cash flows are due, among other things, to increased investments, including investments in Invendo.
  • Based on the good results for Q2, the outlook for organic growth in local currencies for 2017/18 is raised from ‘approx. 13%’ to ‘approx. 14-15%’. The outlook for EBIT margin and free cash flows is maintained.

A conference call is being held today, 7 May 2018, at 11.00 (CET). Please call the following number five minutes before the start of the conference: +45 3544 5580. The conference can be followed via www.ambu.com/webcastQ22018 and is held in English. The presentation can be downloaded immediately before the conference call via the same link.

Download
You can download the full interim report for Q1 and H1 2017/18 (pdf).

30

Apr. 2018

Completion of share buyback programme (no. 29)

As described in company announcement no. 15 dated 31 January 2018, the Board of Directors has on the same date initiated a share buyback programme based on the authorization given by the general assembly to introduce a share buyback programme. This takes place as set out in the European Commission Regulation No. 596/2014 of 16 April 2014, also called the ‘Safe Harbour rules’. 

The share buyback programme is implemented to cover the LTI incentive programmes which were established on 22 December 2017 as described in company announcement no. 11 and 12 on 22 December 2017. During the share buyback programme which takes place from 1 February 2018 to 30 April 2018, Ambu plans to acquire own shares at a total of up to 3,850,000 shares at a total price of up to DKK 560m.

During the share buyback programme, the following transactions were conducted in the period as of 23 April up to and including 26 April 2018:

  Number of shares Average
purchase price
Value of the programme in DKK
In total, latest announcement 3,537,000 126.68 448,067,295
23 April 2018 80,000 145.52 11,641,840
24 April 2018 80,000 146.04 11,683,368
25 April 2018 80,000 142.56 11,404,984
26 April 2018 73,000 139.83 10,207,400
In total during the share buyback programme 3,850,000 128.05 493,004,887

Consequently, Ambu owns 8,340,569 shares corresponding to 3.326% of the share capital (A and B shares) and the announced share buyback programme is hereby completed.

Download
You can download this company announcement incl. list of transactions (pdf).

Financial Reports

Get the latest annual & quarterly reports
Read more

Annual Key Figures

Get an overview of Ambu's key figures
Read more

Presentations

Get the latest investor presentations and webcasts
Read more

Strategy

Learn more about Ambu's present strategy
Read more

Upcoming events

23

May. 2018

Handelsbanken Nordic Mid/Small Cap Seminar 2018

Stockholm
23-24 May 2018

05

Jun. 2018

Jefferies 2018 Healthcare Conference

New York
5-8 June 2018

19

Jun. 2018

Danske Bank Q2 roadshow Europe

19-21 June 2018

News from Ambu

Sign up and receive news and company announcements from Ambu

Sign up

 

keyboard_arrow_up
代孕 | 代孕 | 代孕 | 北京代孕 | 深圳代孕 | 武汉代孕 | 武汉代孕 | 上海代孕 | 武汉代孕 | 捐卵